Metabolic & Cardiometabolic
resistant starch improves insulin resistance
In plain terms: Does resistant starch help your body handle blood sugar?
Contested Metabolic & Cardiometabolic 🔬 Includes disconfirming
Part of: 🧪 resistant starch
RefutedContestedStrong support
consensus score 0.01
Unclear. Some small trials found improvement, but pooled analyses and a 12-week diabetes trial found no consistent effect on insulin resistance. Blood-sugar measures respond more reliably, and a benefit limited to insulin-resistant people is not established.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
6 support 6 contradict 1 tested null 4 mixed · 17 sources, 12 independent groups · 3 superseded — pooled inside a review, counted once
What the evidence shows
Contested — the trials split on whether resistant starch improves insulin resistance itself. Several small RCTs report benefit (a 25 g/d HAM-RS2 bagel crossover in 24 at-risk adults lowered HOMA-IR 23.
The evidence (20)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Bergeron N, Williams PT, Lamendella R, Faghihnia N, Grube A, Li X, Wang Z, Knight R, Jansson JK, Hazen SL, Krauss RM 2016 · Br J Nutr | RCT | contradicts | moderate | 2-wk high-RS diet did not improve fasting glucose, insulin or lipids; raised TMAO under low-carb |
| Kim HR, Park HR, Kang YR, Choi HD, Shin KS, Hong JS 2026 · Carbohydrate polymers | animal | contradicts | low | Duplicate/earlier posting of RS5 (rice-starch beta-limit dextrin-lauric acid) mouse study: no significant OGTT or insulin-resistance change after 5wk supplementation. |
| Zeng J, Li P, Chen H, Li F, He X, Liu G, Zhou P, Zhao Z, Zhang Y, Zhang M, Deng Y 2026 · NPJ science of food | animal | supports | moderate | RS-rich rice varieties (RSRR), HFD-induced T2D mice, 6wk: reduced fasting glucose, serum insulin, and improved insulin resistance vs common-rice control; KTD variety most effective. |
| Gao C, Rao M, Huang W, Wan Q, Yan P, Long Y, Guo M, Xu Y, Xu Y 2019 · Lipids Health Dis | meta-analysis | mixed | moderate | SR/MA: resistant starch ameliorated insulin resistance (HOMA-IR) in patients with type 2 diabetes and obesity. |
| Suárez-Diéguez T, Olvera Nájera M, Silva M, López-Rodríguez G, Ariza-Ortega JA, García-Tejedor A, Nieto JA 2025 · Nutrients | animal | supports | low | Retrograded RS (RS3, faba bean-derived) 15-30% diet replacement, diabetic Wistar rats: ~29% lower postprandial hyperglycemia, 22% lower fasting glucose, lower insulin-resistance index; no lipid/oxidative-stress effect. |
| Schioldan AG, Gregersen S, Hald S, Bjørnshave A, Bohl M, Hartmann B, Holst JJ, Stødkilde-Jørgensen H, Hermansen K 2018 · Eur J Nutr | RCT | mixed | moderate | Arabinoxylan+RS diet improved some postprandial metabolic features of metabolic syndrome vs refined carbohydrate, with limited IR change. |
| Karimi P, Farhangi MA, Sarmadi B, Gargari BP, Zare Javid A, Pouraghaei M, Dehghan P 2016 · Ann Nutr Metab | RCT | supports | moderate | RS2 improved glycemic status and reduced insulin resistance, endotoxemia and oxidative stress in women with T2D. ↩ SUPERSEDED — pooled in the review above, counted once |
| King TL, Bugam SH, Khoo SY, Tan SH, Yeo JJP, Tan SSN, Chan PY, Liew NK, Chunggat J, Tiong LL, Ibrahim AS, Tan FHS, Tiong XT 2025 · Clin Nutr ESPEN | RCT | contradicts | moderate | Double-blind RCT in type 2 diabetes (100 randomised, 82 analysed, 12 wk): 50 g/day sago starch (RS2-rich) vs 50 g/day corn starch. No between-group change in HOMA-IR (-0.22 [95% CI -1.04 to 0.60]; p = 0.590), fasting insulin (-0.31 mIU/L [-2.74 to 2.11]), fasting glucose or HbA1c (-0.03% [-0.24 to 0.19]); lipids also unchanged. Authors: '12-week of sago starch supplementation did not result in significant improvement in glycaemic and lipid parameters in patients with type 2 diabetes.' Abstract only. |
| Costa ES, França CN, Fonseca FAH, Kato JT, Bianco HT, Freitas TT, Fonseca HAR, Figueiredo Neto AM, Izar MC 2019 · Br J Nutr | RCT | supports | moderate | Green-banana-biomass RS lowered HbA1c, fasting glucose and HOMA-IR in pre-diabetes/T2D over 24 weeks. |
| Robertson MD, Bickerton AS, Dennis AL, Vidal H, Frayn KN 2005 · Am J Clin Nutr | RCT | supports | moderate | Dietary RS improved peripheral insulin sensitivity and modulated skeletal-muscle/adipose metabolism in healthy adults. ↩ SUPERSEDED — pooled in the review above, counted once |
| Snelson M, Jong J, Manolas D, Kok S, Louise A, Stern R, Kellow NJ 2019 · Nutrients | meta-analysis | contradicts | high | 22-RCT meta-analysis: RS2 lowered triglycerides but showed no consistent improvement in fasting glucose, HbA1c or insulin resistance. |
| Dainty SA, Klingel SL, Pilkey SE, McDonald E, McKeown B, Emes MJ, Duncan AM 2016 · J Nutr | RCT | supports | moderate | Randomised double-blind crossover, n=24 adults at increased T2D risk (mean age 55, BMI 30): 25 g/d HAM-RS2 bagel vs control wheat bagel for 56 d each, 4-wk washout. HOMA-IR 23.1% lower (P=0.04), fasting insulin iAUC -22.1% (P=0.04), 2-h OGTT insulin iAUC -23.3% (P<0.008) vs control; OGTT glucose unchanged. NCT02129946. Abstract-only. ↩ SUPERSEDED — pooled in the review above, counted once |
| Xiong K, Wang J, Kang T, Xu F, Ma A 2021 · Br J Nutr | meta-analysis | supports | moderate | 19 RCTs FPG -0.09 mmol/L; larger >28g/d; modest dose-dependent |
| Jaroenporn S, Fainanta T, Tananuwong K, Saradhuldhat W, Jatuyosporn T, Krusong K 2026 · Nutrition research (New York, N.Y.) | animal | contradicts | moderate | Cassava RS3 in isocaloric HFD, healthy Wistar rats 28d: fasting glucose, insulin, and lipids statistically unchanged vs HFD-native-starch; only modest early glucose-tolerance improvement. |
| White U, Peterson CM, Beyl RA, Martin CK, Ravussin E 2020 · J Acad Nutr Diet | RCT | tested-null | moderate | RS2 had no effect on appetite/food intake in prediabetes; part of STARCH program testing diabetes risk factors. |
| Miralles-Pérez B, Ramos-Romero S, Charpentier MJ, Sánchez-Martos V, Fortuño-Mar À, Ponomarenko J, Amézqueta S, Piñol-Piñol D, Zhang X, Torres JL, Romeu M 2025 · Molecular nutrition & food research | animal | contradicts | moderate | RS2 (15%, high-amylose maize) in HFD, male Wistar rats, 10wk: improved glucose tolerance but did NOT significantly affect insulin sensitivity vs HFD control. |
| Halajzadeh J, Milajerdi A, Reiner Ž, Amirani E, Kolahdooz F, Barekat M, Mirzaei H, Mirhashemi SM, Asemi Z 2020 · Crit Rev Food Sci Nutr | meta-analysis | mixed | moderate | Meta-analysis of 19 RCTs of resistant starch in metabolic syndrome and related disorders (abstract-grade). On the insulin-resistance object the two indices point opposite ways: fasting insulin fell — 'insulin (12 studies) (WMD: -1.95; 95% CI: -3.22, -0.68)' — but the direct IR index did not move: 'it did not affect HOMA-IR' (HOMA-IR study count and estimate not given in abstract). Glycaemia improved (FPG, 14 studies, WMD -4.28 mg/dL-scale, 95% CI -7.01 to -1.55; HbA1c, 8 studies, -0.60, 95% CI -0.95 to -0.24), but glycaemia is not insulin resistance. Mixed on the object; per-outcome denominators are subsets of the 19 trials. |
| Park J, Oh SK, Doo M, Chung HJ, Park HJ, Chun H 2023 · Nutrients | RCT | supports | moderate | High-RS brown rice (Dodamssal) reduced HOMA-IR vs low-RS rice in obese participants. |
| Im ST, Park HY, Kim HR, Son SJ, Ryu AR, Hong JS, Choi HD, Kang MC 2026 · Journal of food science | animal | supports | moderate | RS-enriched high-amylose rice (R-HAR), HFD obese mice: markedly reduced fasting insulin & HOMA-IR vs HFD control, dose-dependent, alongside lower fasting glucose; no CIs given. |
| García-Vázquez C, Ble-Castillo JL, Arias-Córdova Y, Ramos-García M, Olvera-Hernández V, Guzmán-Priego CG, Martínez-López MC, Jiménez-Domínguez G, Hernández-Becerra JA 2023 · Eur J Nutr | RCT | mixed | moderate | RS improved acute glycemic response in T2D but chronic IR benefit not established |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.